clinical trial · NCT06007677
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Astria Therapeutics, Inc.·phase2·active not recruiting·n = 56
Hereditary AngioedemaSTAR-0215
brief summary
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
started
Sep 26, 2023
primary completion
Mar 1, 2031
completion
Mar 1, 2031
last updated
Jul 23, 2025
official title
A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol